Clinical Trials
32
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (32 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.
- Conditions
- Non-segmental Vitiligo
- Interventions
- Drug: VYN201 GelDrug: Vehicle Gel
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Vyne Therapeutics Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT06493578
- Locations
- 🇺🇸
Cahaba Dermatology & Skin Health Center, Birmingham, Alabama, United States
🇺🇸Saguaro Dermatology, Phoenix, Arizona, United States
🇺🇸Center for Dermatology and Plastic Surgery/CCT Research, Scottsdale, Arizona, United States
Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis
- First Posted Date
- 2021-06-16
- Last Posted Date
- 2022-08-31
- Lead Sponsor
- Vyne Therapeutics Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT04927572
- Locations
- 🇺🇸
Investigator #9, Miami, Florida, United States
🇺🇸Investigator #14, Miami, Florida, United States
🇺🇸Investigator #12, Miramar, Florida, United States
A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
- Conditions
- Facial Papulopustular Rosacea
- Interventions
- Drug: Vehicle foam
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2021-01-07
- Lead Sponsor
- Vyne Therapeutics Inc.
- Target Recruit Count
- 771
- Registration Number
- NCT04608500
- Locations
- 🇺🇸
Foamix Investigational Site # 207, Glendale, Arizona, United States
🇺🇸Foamix Investigational Site # 202, Hot Springs, Arkansas, United States
🇺🇸Foamix Investigational Site # 222, Rogers, Arkansas, United States
A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.
- Conditions
- Acne Vulgaris
- Interventions
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2021-02-05
- Lead Sponsor
- Vyne Therapeutics Inc.
- Target Recruit Count
- 446
- Registration Number
- NCT04104685
- Locations
- 🇺🇸
Foamix Institution #134, Bryant, Arkansas, United States
🇺🇸Foamix Institution #121, Rogers, Arkansas, United States
🇺🇸Foamix Institution #106, Encino, California, United States
Dermal Photo Allergic Skin Reaction
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Vyne Therapeutics Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT04070755
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
News
Vitiligo Treatment Pipeline Shows Promise with JAK Inhibitors and Novel Immunotherapies in Phase 3 Trials
Over 18 companies are actively developing 20+ pipeline therapies for vitiligo treatment, with JAK inhibitors leading the charge in late-stage clinical trials.
VYNE Therapeutics' Repibresib Gel Fails to Meet Primary Endpoints in Phase 2b Vitiligo Trial
VYNE Therapeutics announced that its phase 2b trial of repibresib gel in nonsegmental vitiligo failed to meet primary and key secondary endpoints, with only 19.5% of patients achieving F-VASI50 improvement compared to 23.4% on vehicle.
MindMed Appoints Matt Wiley as Chief Commercial Officer to Lead MM120 Launch Strategy
MindMed has appointed Matt Wiley as Chief Commercial Officer to oversee the commercial strategy for MM120 ODT, a potential treatment for generalized anxiety disorder and major depressive disorder.
VYNE Therapeutics Advances VYN201 and VYN202 in Vitiligo and Psoriasis Trials
VYNE Therapeutics completes enrollment for Phase 2b trial of VYN201 gel (repibresib) in nonsegmental vitiligo, with top-line data expected mid-2025.
VYN201 Shows Promise in Phase 1b Trial for Non-Segmental Vitiligo
A Phase 1b trial of VYN201 topical gel demonstrated safety and tolerability in patients with active non-segmental vitiligo (aNSV).